Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

I.V. PREMIXED DRUG CARTRIDGE SYSTEM IS "TECHNICALLY FEASIBLE," but manufacturing costs are delaying commercial viability, Abbott Hospital Product Division VP Sales & Marketing Robert Parkingson, Jr., told a Sept. 14 symposium in NYC sponsored by the Wilkerson Group. "A prefilled syringe of drug that avoids labor in the pharmacy and can be clipped in a syringe infusor on the [hospital] floor is technically feasible," Parkinson said. "What we haven't figured out," Parkinson continued, "is how to manufacture it at a low enough cost." Bonnie Kirschenbaum director of Pharmacy Services at National Medical Enterprises (NME) suggested the need for such a product. "If some one were smart enough to be able to prepare a premixed or frozen product in some sort of cartridge system that can ultimately slip into the syringe pump delivery system . . . so that I don't have to be in the manufacturing business of the pharmacy, that would be a whole lot more appealing to me," Kirschenbaum said. Abbott, which markets the Add-Vantage drug delivery system, reportedly holds 34-37% of the part fill/premix market, competing with Baxter's 56-59% Minibag share. Noting NME's commitment to Baxter, Kirschenbaum commented, "When I look at the sources ofsupply for injectable products, my first choice is something in the frozen premix family." Kirschenbaum cited breadth of product line and a minimum of labor intensiveness as reasons she would choose one I.V. system over another. She expressed a desire for greater diversification of drug delivery systems from companies such as Abbott and Baxter, pointing out that hospitals often resort to a "mishmash of several different types of products" to fulfill their needs. From the prospective of a hospital purchaser, "those of you representing the pharmaceutical industry . . . need to realize that when you are bringing a new product to market it is extremely important to realize no longer are you only in the drug business, but you are also in the drug delivery business, whether you want to be or not," Kirschenbaum said.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts